Advertisement
Canada markets closed
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7321
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    83.81
    +0.24 (+0.29%)
     
  • Bitcoin CAD

    87,931.52
    -34.57 (-0.04%)
     
  • CMC Crypto 200

    1,391.38
    +8.81 (+0.64%)
     
  • GOLD FUTURES

    2,344.90
    +2.40 (+0.10%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,782.75
    +215.25 (+1.23%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     
  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Analysts Are Mostly Positive on Neurocrine Biosciences

Analysts Are Mostly Positive on Neurocrine Biosciences

Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.